Sort   by:  
 Page size 
ProteomicsPharmacological Targeting of Casein Kinase 1δ Suppresses Oncogenic NRAS-Driven Melanoma
Activating mutations in NRAS account for 20-30% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K, which are the most prevalent NRAS mutations ...
ORGANISM(S): Homo sapiens (Human) 
2024-09-20 | PXD046277 | Pride
Oncogenic nras melanomagenesis  melanoma progression ck1δ  usp46. 
TranscriptomicsOncogenic Nras has a bimodal effect on hematopoietic stem cells promoting proliferation and self-renewal
Pre-leukemic mutations are thought to promote clonal expansion of hematopoietic stem cells (HSCs) by increasing self-renewal and competitiveness. However, mutations that increase HSC proliferation tend to reduce competitiveness and self-renewal potential, raising the question of how a mutant HSC can...
ORGANISM(S): Mus musculus 
2014-03-14 | E-GEOD-45194 | biostudies-arrayexpress
ProteomicsDynamic conformational equilibria in the active states of KRas and NRas
The design of potent RAS inhibitors benefits from a molecular understanding of the dynamics in KRAS and NRAS and their oncogenic mutants. Here we characterize switch-1 dynamics in GTP-state KRAS and NRAS by 31P NMR, by 15N relaxation dispersion NMR, hydrogen-deuterium exchange mass spectrometry (HDX...
ORGANISM(S): Homo sapiens (Human) 
2025-05-07 | PXD054924 | Pride
Ras inhibitors  nras  kras  hdx-ms  hydrogen/deuterium exchange mass spectrometry  oncogenic mutants 
ProteomicsPharmacological Targeting of Casein Kinase 1δ Suppresses Oncogenic NRAS-Driven Melanoma
Activating mutations in NRAS account for 15-20% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K, which are the most prevalent NRAS mutations ...
ORGANISM(S): Homo sapiens (Human) 
2024-09-19 | PXD051431 | Pride
Nras melanoma 
TranscriptomicsGlobal Gene Expression of hematopoietic stem cells expressing endogenous NrasG12D/G12D, NrasG12D/+, Nras+/+
Oncogenic NRAS mutations are frequently identified in human myeloid leukemias. In mice, expression of endogenous oncogenic Nras (NrasG12D/+) in hematopoietic cells leads to expansion of myeloid progenitors, increased long-term reconstitution of bone marrow cells, and a chronic myeloproliferative neo...
ORGANISM(S): Mus musculus 
2013-05-29 | E-GEOD-46948 | biostudies-arrayexpress
TranscriptomicsGene expression profiling of oncogenic NRAS driven mouse melanomas that have developed resistance to NRAS withdrawal
Targeted therapies have the potential to revolutionize cancer care by providing personalized treatment strategies that are less toxic and more effective but it is clear that for most solid tumors suppression of a single target is not sufficient to prevent development of resistance. A powerful method...
ORGANISM(S): Mus musculus 
2014-10-31 | E-GEOD-51906 | biostudies-arrayexpress
TranscriptomicsEffect of DNMT3A R882H mutation or WT on gene expression in hematopoietic stem/progenitor cells with NRAS G12D co-transduction (Microarray)
DNA Methyltransferase 3A (DNMT3A) is frequently mutated in various hematopoietic malignancies; however, the underlying oncogenic mechanisms remain elusive. Here, we report that DNMT3A mutational â??hotspotâ?? at Arg882 (i.e., DNMT3A-R882H) cooperates with constitutively activated RAS in transforming...
ORGANISM(S): Mus musculus 
2016-06-23 | E-GEOD-71437 | biostudies-arrayexpress
UnknownPharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma.
Not available
S-EPMC11582648 | biostudies-literature
TranscriptomicsOncogenic potential of RAS isoforms in melanocytes
We compared the transformation efficiencies of mutant NRAS and KRAS in immortal, non-transformed Ink4a/Arf-deficient melanocytes. NRAS mutation leads to increased cellular proliferation and is potently tumorigenic. In contrast, KRAS mutation does not enhance melanocyte proliferation and is only weak...
ORGANISM(S): Mus musculus 
2010-06-10 | E-GEOD-6194 | biostudies-arrayexpress
GenomicsEffect of DNMT3A R882H mutation or WT expression on epigenetic landscapes of hematopoietic stem/progenitor cells with NRAS G12D co-transduction (ChIP-seq)
DNA Methyltransferase 3A (DNMT3A) is frequently mutated in various hematopoietic malignancies; however, the underlying oncogenic mechanisms remain elusive. Here, we report that DNMT3A mutational ‘hotspot’ at Arg882 (DNMT3A-R882H) cooperates with constitutively activated RAS in transforming murin...
ORGANISM(S): Mus musculus 
2016-06-23 | E-GEOD-71472 | biostudies-arrayexpress
Sort   by:  
 Page size